Using germline genotype in cancer pharmacogenetic studies

Pharmacogenomics

Volumn 10, Issue 3, 2009, Pages 489-493

  McWhinney, Sarah R ^a   McLeod, Howard L ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Germline; Pharmacogenetics; Somatic

Indexed keywords

DNA; GERMLINE DNA; SOMATIC DNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER RESEARCH; CANCER TISSUE; COLORECTAL CANCER; COMPARATIVE STUDY; DNA DETERMINATION; DNA EXTRACTION; EXON; GENETIC RESOURCE; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; NEOPLASM; PHARMACOGENETICS; SAMPLING; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC CELL; TISSUE PREPARATION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR CELL LINE; ZYGOSITY;

DNA; DNA, NEOPLASM; GENOTYPE; GERM CELLS; GERM-LINE MUTATION; HUMANS; PHARMACOGENETICS;

EID: 66849106721     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.10.3.489     Document Type: Article

References (16)

1. Marsh S, Mallon MA, Goodfellow P, McLeod HL: Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics 6(8), 873-877 (2005).
2. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD: Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 13(8), 501-507 (2003).
3. Weiss JR, Baer MR, Ambrosone-CB et al.: Concordance of pharmacogenetic pa,lymorphisms in tumor and germ line DNA in adult patients with acute myeloid leukemia, Cancer Epidemiol. Biomarkers Prev. 16(5). 1038-1041 (2007).
4. Schneider BP, Radovich M, Sledge GW et al.: Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res. Treat. 111(1), 157-163 (2007).
5. Xie B, Freudenheim JL, Cummings SS et al.: Accurate genotyping from paraffin-embedded normal tissue adjacent to breast cancer. Carcinogenesis 27(2), 307-310 (2006).
6. Evans WE, McLeod HL: Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med. 348(6), 538-549 (2003).
7. Deng G, Lu Y, Zlotnikov G, Thor AD, Smith HS: Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274(5295), 2057-2059 (1996).
8. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL: CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br. J. Cancer 88(6), 928-932 (2003).
9. Sebolt-Leopold JS, English JM: Mechanisms of drug inhibition of signalling molecules. Nature 441(7092), 457-462 (2006).
10. Irmer D, Funk JO, Blaukat A: EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene 26(39), 5693-5701 (2007).
11. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G: Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 8, 10 (2008).
12. Ikediobi ON: Somatic pharmacogenomics in cancer. Pharmacogenomics J. 8(5), 305-314 (2008).
13. Gorre ME, Mohammed M, Ellwood K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531), 876-880 (2001).
14. Rapley EA, Hockley S, Warren W et al.: Somatic mutations of KIT in familial testicular germ cell tumours. Br. J. Cancer 90(12), 2397-2401 (2004).
15. Demetri GD: Identification and treatment of chemoresistant inoperable or metastatic GIST. experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur. J. Cancer 38(Suppl. 5), S52-S59 (2002).
16. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J Oncol. 19(2), 383-386 (2001).